Custom market research built around the exact strategic decision you're facing — not a template. Delivered in 2–4 weeks, backed by primary data, reviewed by senior domain analysts.
NDA before kick-off · No commitment required · Response within 1 business day
All information strictly confidential · NDA before kick-off · No spam
We'll respond within 1 business day at — with either a scoped proposal or a call booking link depending on what you selected.
"ConsaInsights delivered exactly what we needed to walk into the board meeting with confidence — not assumptions. The research was specific to our indication, primary-backed, and ready to present."
VP Strategy, Clinical-stage Biotech · Series B preparation engagement
Off-the-shelf reports are built for everyone. Here's what that costs biotech leaders every time they rely on them.
Broad oncology or immunology reports exist. Reports specific to your molecule, subpopulation, or niche geography don't — until you commission one. Generic data doesn't hold up to board or LP scrutiny.
Building deep competitive or market access intelligence internally takes months. Portfolio reviews, BD windows, and fundraising timelines don't wait for internal teams to catch up.
Licensing negotiations, Series B decks, and investment diligence require primary-backed, methodology-documented intelligence. A chart from a public database gets challenged in the room.
You're in the right place. And if your situation isn't listed — the last card is for you.
Market sizing, competitive landscapes, M&A target screens — defensible methodology, 2–4 weeks.
Pipeline benchmarking, KOL insights, regulatory pathway intelligence — specific to your indication.
Commercial diligence, deal benchmarks, partner identification — before you commit to the conversation.
Board-ready market assessments, investment validation, and foresight decks — built for your audience.
GTM strategy research, patient/physician segmentation, geographic feasibility, competitive positioning.
Our brief-scoping process is built for situations that don't fit a template.
Tell us your situation →A dedicated TA-specialist analyst is assigned from day one. No generalists. No templates.
Describe your decision. We respond within 24 hours with a scoped methodology and cost estimate.
Your TA-specialist analyst executes — primary KOL interviews, clinical databases, and curated secondary intelligence.
Findings synthesised into models and reviewed by a senior domain lead. Every number traceable. Every insight defensible.
Executive report + market model + analyst debrief call. One revision round included until the research answers your question precisely.
Executive summary (15–25 pg) · Editable market model · Competitive pipeline map · Methodology appendix · Analyst debrief call · Revision round included
Every engagement is staffed by an analyst with dedicated expertise in your indication. You're never assigned someone learning your disease area on your timeline.
Deliverables are designed backward from the decision you need to make — board-ready format, executive narrative, and recommendations your team can act on immediately.
All briefs and deliverables are covered by NDA from the first conversation — before any scoping discussion. We never reuse or reference client intelligence in other engagements. Happy to sign your NDA template.
Boutique agility without the overhead of large consulting firms. When your board meeting or BD window opens, the research is already in your hands.
Don't see yours? There's an escape hatch at the bottom.
Have a question that isn't here?
Ask us in your brief — we'll answer before we propose →Submit a research brief, book a discovery call, or request a strategy scoping session. Every path leads to a senior analyst — not a sales rep.
NDA before kick-off · Proposal or call booked within 1 business day · No spam
500+ biotech teams chose Consainsights. Next analyst availability is limited.